shutterstock_246073315.jpg
shutterstock_246073315.jpg
shutterstock_373528693_small.jpg
shutterstock_317504351.jpg
shutterstock_246073315.jpg

Overview


Novel TRPV1 Agonist Prodrugs for Pain

SCROLL DOWN

Overview


Novel TRPV1 Agonist Prodrugs for Pain

We are developing a portfolio of novel, non-opioid therapeutics that provide long-lasting pain relief after a single local administration.

shutterstock_246073315.jpg

Attributes


Attributes of our prodrug

Attributes


Attributes of our prodrug

Reduced opioid consumption & opioid-related AE's

Non-opioid


Targets pain at source with limited systematic exposure

Site Specific


Single injection simplifies ongoing care & adherence

SIMPLE


Continuous and extended relief

Long lasting


PAIN-SELECTIVE

Extended pain relief without numbness or weakness

shutterstock_373528693_small.jpg

The Problem


The Problem

 

The Problem


The Problem

 

Current Postsurgical Treatment Options Fall Short

There is no “good” way to provide continuous, effective pain relief beyond the first 18 – 24 hours after surgery.

  • Treating pain systemically with opioids (e.g. Vicodin®, morphine) provides relief but dramatically increases costs and morbidity
  • Treating pain at its source with local anesthetic is highly effective yet limited as a result of its short duration of action
  • Treating pain with conduction blocks is highly effective, but clinically cumbersome and costly 

Current Osteoarthritis Treatment Options Fall Short

There is no “good” way to provide durable, effective relief for moderate to severe osteoarthritis pain

  • NSAIDS only effective for mild-to-moderate and have significant safety issues (GI, Renal, CV)
  • Opioids provide relief but dramatically increase costs and morbidity
  • Intra-articular steroids ("IA") are somewhat effective yet limited due to short duration of action
  • IA hyaluronic acid has limited differentiation from placebo in controlled clinical studies
Body.png
shutterstock_317504351.jpg

Goal


Goal

 

Goal


Goal

 

Our goal is to drive the actualization of value-based health care by substantially reducing costs, improving outcomes and reducing intensivity of care.

 
  • Decrease opioid use and harmful, costly sequelae

  • Increase patient satisfaction (HCAHPS)

  • Superior patient-reported outcomes versus standard of care

  • Improve functional outcomes

  • Reduce lost-days-of-work and hasten return to productivity

  • REDUCE UnNECESSaRY HOSPITAL COSTS INCLUDING: DECREASE TIME TO DISCHARGE and DECREASE ER VISITS AND Re-ADMITTANCE